Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alexion Pharmaceuticals Inc (NASDAQ:ALXN)

119.26
Delayed Data
As of Mar 24
 -1.00 / -0.83%
Today’s Change
109.12
Today|||52-Week Range
162.00
-2.53%
Year-to-Date
Alexion (ALXN) Files for Soliris' Label Expansion in Japan
Mar 23 / Zacks.com - Paid Partner Content
Alexion (ALXN) Licenses Artubus Technology for Rare Diseases
Mar 17 / Zacks.com - Paid Partner Content
Biotech Premarket Movers: Insys, Ultragenyx, Alexion
Mar 23 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close120.26
Today’s open120.94
Day’s range118.73 - 121.43
Volume1,292,350
Average volume (3 months)2,542,478
Market cap$26.8B
Dividend yield--
Data as of 4:14pm ET, 03/24/2017

Growth & Valuation

Earnings growth (last year)+162.69%
Earnings growth (this year)+12.94%
Earnings growth (next 5 years)+23.70%
Revenue growth (last year)+21.11%
P/E ratio67.8
Price/Sales9.22
Price/Book3.07

Competitors

 Today’s
change
Today’s
% change
ZTSZoetis Inc+0.05+0.09%
BAXBaxter International...+0.33+0.64%
INCYIncyte Corp+0.67+0.48%
VRTXVertex Pharmaceutica...+0.93+1.04%
Data as of 4:05pm ET, 03/24/2017

Financials

Next reporting dateApril 27, 2017
EPS forecast (this quarter)$1.24
Annual revenue (last year)$3.0B
Annual profit (last year)$399.0M
Net profit margin13.25%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
David Richard Brennan
Executive Vice President-
Global Operations
Julie O'Neill
Corporate headquarters
New Haven, Connecticut

Forecasts


Search for Jobs